Based on the principle of Gamma Interferon Gamma Release Assay (IGRA), it can detect whether the subjects have mycobacterium tuberculosis-specific lymphocytes through the enzyme-linked immunospot technique (ELISPOT), so that it can determine whether the subjects are infected with mycobacterium tuberculosis. The ELISPOT technology platform is used to break through the traditional ELISA method, with a specificity and sensitivity rate as high as 95%. The detection is fast and accurate, and it is recommended for use at home and abroad.
The new ELISPOT for tuberculosis infection can well distinguish tuberculosis infection from non-tuberculosis mycobacteria infection, without being affected by BCG vaccination, solving the problem of tuberculosis infection, especially tuberculosis latent infection diagnosis. The tuberculosis infection detection kit which is developed based on the technical achievement is unique and eligible for patent protection.
Product Advantages:
Good specificity, only sensitive to MTB, without cross reaction with most environmental mycobacteria and BCG
High sensitivity, basically not affected by low immunity
There is a high detection rate among patients with extra-pulmonary tuberculosis
The sensitivity of detecting tuberculosis is as high as 95.56% when it is based on bacteriological diagnosis of tuberculosis
Fast and simple, report can be generated within 24 hours